Circassia Pharmaceuticals ( (GB:NIOX) ) just unveiled an update.
NIOX Group plc, a company listed on the AIM market, has issued 363,006 new ordinary shares to its Executive Directors as part of its Deferred Share Bonus Plan. This issuance, related to the 2022 financial year’s annual bonus, follows the release of the company’s year-end results and marks the end of its closed period. The new shares are part of an existing block admission and align with the company’s remuneration policy, which defers a portion of bonuses for two years. This move reflects NIOX’s commitment to aligning executive incentives with shareholder interests, potentially impacting the company’s stock liquidity and executive shareholding structure.
More about Circassia Pharmaceuticals
YTD Price Performance: 20.63%
Average Trading Volume: 945,041
Technical Sentiment Signal: Sell
Current Market Cap: £301.2M
Learn more about NIOX stock on TipRanks’ Stock Analysis page.